Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.
Speaker 3: (00:32)
Would you tell us a little bit about yourself and your history with this testing?
Speaker 3: (01:25)
Would you tell us a little more about this assay?
Speaker 3: (04:57)
Which patients should have this testing and when should it be performed?
Speaker 3: (05:30)
What alternative tests exist and how do they compare?
Speaker 3: (06:28)
How are the results used in patient care?